ATE328112T1 - Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon - Google Patents

Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon

Info

Publication number
ATE328112T1
ATE328112T1 AT03005186T AT03005186T ATE328112T1 AT E328112 T1 ATE328112 T1 AT E328112T1 AT 03005186 T AT03005186 T AT 03005186T AT 03005186 T AT03005186 T AT 03005186T AT E328112 T1 ATE328112 T1 AT E328112T1
Authority
AT
Austria
Prior art keywords
reagents
compositions
testing methods
anaplastic lymphoma
lymphoma kinase
Prior art date
Application number
AT03005186T
Other languages
English (en)
Inventor
Lorenzo A Pinna
Arianna Donella-Deana
Oriano Marin
Luca Mologni
Rosalind Gunby
Passerini Carlo Gambacorti
Leonardo Scapozza
Original Assignee
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Naz Stud Cura Dei Tumori filed Critical Ist Naz Stud Cura Dei Tumori
Application granted granted Critical
Publication of ATE328112T1 publication Critical patent/ATE328112T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03005186T 2003-03-07 2003-03-07 Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon ATE328112T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03005186A EP1454992B1 (de) 2003-03-07 2003-03-07 Anaplastisches Lymphoma Kinase Testverfahren, Reagenzien und Kompositionen davon

Publications (1)

Publication Number Publication Date
ATE328112T1 true ATE328112T1 (de) 2006-06-15

Family

ID=32798804

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03005186T ATE328112T1 (de) 2003-03-07 2003-03-07 Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon

Country Status (14)

Country Link
US (1) US20070031907A1 (de)
EP (1) EP1454992B1 (de)
JP (1) JP2006519800A (de)
CN (1) CN100345978C (de)
AT (1) ATE328112T1 (de)
CA (1) CA2518094A1 (de)
CY (1) CY1106115T1 (de)
DE (1) DE60305634T2 (de)
DK (1) DK1454992T3 (de)
ES (1) ES2263862T3 (de)
IL (1) IL170669A0 (de)
PT (1) PT1454992E (de)
SI (1) SI1454992T1 (de)
WO (1) WO2004079326A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
EP2107054A1 (de) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative Verbindungen und therapeutische Verwendungen dafür
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2161271A1 (de) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-Carbolin-Hemmer von NMP-ALK, RET und Bcr-Abl
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
ES2668775T3 (es) 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
CN101955995B (zh) * 2010-06-17 2013-06-26 江苏迈迪基因生物科技有限公司 淋巴瘤相关的融合基因的诊断试剂盒
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
EP2606886B1 (de) 2010-08-20 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Zusammensetzung umfassend eine tetrazyklische verbindung
EP4026912A1 (de) 2012-05-10 2022-07-13 The General Hospital Corporation Verfahren zur bestimmung einer nukleotidsequenz
PL2902029T3 (pl) 2012-09-25 2019-01-31 Chugai Seiyaku Kabushiki Kaisha Inhibitor RET
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
AU2015209079B2 (en) 2014-01-27 2021-07-15 Archerdx, Llc Methods of preparing nucleic acids for sequencing
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 4環性化合物を高用量含有する製剤
RU2016146119A (ru) 2014-04-25 2018-05-29 Чугаи Сейяку Кабусики Кайся Новый кристалл тетрациклического соединения
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 4環性化合物的非晶質體
TWI752901B (zh) 2015-01-16 2022-01-21 日商中外製藥股份有限公司 合併用醫藥
CA3037190A1 (en) 2016-09-15 2018-03-22 ArcherDX, Inc. Methods of nucleic acid sample preparation for analysis of cell-free dna
CN109937254B (zh) 2016-09-15 2023-05-30 阿谢尔德克斯有限责任公司 核酸样品制备方法
US12630864B2 (en) 2016-09-15 2026-05-19 Laboratory Corporation Of America Holdings Methods of nucleic acid sample preparation
CA3042391A1 (en) 2016-11-02 2018-05-11 ArcherDX, Inc. Methods of nucleic acid sample preparation for immune repertoire sequencing
BR112020025499A2 (pt) 2018-06-29 2021-03-09 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica que compreende agente básico pouco solúvel
TWI825163B (zh) 2018-09-04 2023-12-11 日商中外製藥股份有限公司 四環性化合物的製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05126833A (ja) * 1991-10-31 1993-05-21 Tosoh Corp チロシンキナ−ゼ活性の免疫化学的測定法及びそのキツト
WO1993021230A1 (en) * 1992-04-10 1993-10-28 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
EP0575955B1 (de) * 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur Herstellung von Staurosporin-Derivaten
GB9314271D0 (en) * 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
JP3442784B2 (ja) * 1993-11-23 2003-09-02 ジェネンテク,インコーポレイテッド キナーゼ受容体活性化検定法
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
JP2002513289A (ja) * 1997-04-28 2002-05-08 スージェン・インコーポレーテッド チロシンホスファターゼ関連疾患の診断および治療および関連する方法
AU6014900A (en) * 1999-07-13 2001-01-30 Kyowa Hakko Kogyo Co. Ltd. Staurosporin derivatives

Also Published As

Publication number Publication date
DE60305634D1 (de) 2006-07-06
CN1756850A (zh) 2006-04-05
SI1454992T1 (sl) 2006-10-31
WO2004079326A2 (en) 2004-09-16
PT1454992E (pt) 2006-09-29
CA2518094A1 (en) 2004-09-16
US20070031907A1 (en) 2007-02-08
WO2004079326A3 (en) 2004-12-09
HK1068154A1 (en) 2005-04-22
DK1454992T3 (da) 2006-10-02
EP1454992B1 (de) 2006-05-31
JP2006519800A (ja) 2006-08-31
DE60305634T2 (de) 2006-09-21
IL170669A0 (en) 2011-08-01
EP1454992A1 (de) 2004-09-08
ES2263862T3 (es) 2006-12-16
CN100345978C (zh) 2007-10-31
CY1106115T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
PT1454992E (pt) Ensaio de quinase do linfoma anaplastico, reagentes e composicoes
WO2005111212A3 (en) Biological bar code
DE69918089D1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
WO2005012574A3 (en) Biological bar-code
EA200501563A1 (ru) Пролекарства ингибиторов киназы pi-3
DK1706424T3 (da) FC-region varianter
DE60007095D1 (de) Calanolide zur hemmung von btk
DK1766412T3 (da) Sammensætninger og fremgangsmåder til kvantificering af serumglycoproteiner
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
DE602004018780D1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
NO20054359L (no) Cykliske protein tyrosin kinase inhibitorer
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
ATE424560T1 (de) Marker für neuromyelitis optica
WO2002047535A3 (en) High throughput assay to detect inhibitors of the map kinase pathway
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
ATE413884T1 (de) Beta-secretase-substrat und seine verwendung
EP2365750A4 (de) Benzoxazol-kinasehemmer und verfahren zu ihrer verwendung
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
WO2004050842A3 (en) Atm kinase compositions and methods
ATE494548T1 (de) Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
BRPI0414365A (pt) composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes
WO2003031941A3 (en) Detection and characterization of pyschoactives using parallel multi-site assays in neuronal tissue
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
NO20033921L (no) Inhibitor av monoaminopptak
ATE457317T1 (de) Chemokine rezeptor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1454992

Country of ref document: EP

REN Ceased due to non-payment of the annual fee